FDG-PET in thyroid cancer

Tumori

Volumn 89, Issue 5, 2003, Pages 540-543

  Crippa, Flavio ^a   Alessi, Alessandra ^a   Gerali, Alberto ^a   Bombardieri, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Differentiated thyroid cancer (DTC); FDG PET; Medullary thyroid cancer (MTC); Thyroid cancer scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CALCITONIN; DOPA; FLUORINE 18; FLUORODEOXYGLUCOSE; IODINE 123; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT THYROTROPIN; SOMATOSTATIN RECEPTOR; SUCCIMER TC 99M; TETROFOSMIN TC 99M; THALLIUM 201; THYROGLOBULIN; THYROTROPIN; THYROXINE;

CANCER RECURRENCE; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; EUROPE; FOLLOW UP; HORMONAL REGULATION; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; IODINE 131 UPTAKE TEST; LITERATURE; MEDIASTINUM LYMPH NODE; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID SCINTISCANNING; WHOLE BODY SCINTISCANNING;

EID: 0347824357     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900517     Document Type: Review

References (38)

1. Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H: Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version2*). Nuklearmedizin, 42: 123-125, 2003.
2. Nakada K, Katoh C, Kanegae K, Tsukamoto E, Shiga T, Mochizuki T, Itoh K, Tamaki N: Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma. J Nucl Med, 39: 807-810, 1998.
3. Yen TC, Lin HD, Lee CH, Chang SL, Yeh SH: The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201. Eur J Nucl Med, 21: 980-983, 1994.
4. Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P: Thyroglobulin and low dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med, 39: 870-875, 1998.
5. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C: Octreotide scintigraphy in patients with differentiated thyroid carcinoma; contribution for patients with negative radioiodine scans. J Clin Endocrinol Metab, 81: 2541-2544, 1996.
6. Lind P, Kumnig G, Matschnig S, Heinisch M, Gallowitsch HJ, Mikos P, Kresnik E, Gomez I, Unterweger O: The role of F-18FDG PET in thyroid cancer. Acta Med Austriaca, 27: 38-41, 2000.
7. Grunwald F, Briele B, Biersack HJ: Non-131I-scintigraphy in the treatment and follow-up of thyroid cancer. Single-photon-emitters or FDG-PET? Q J Nucl Med, 43: 195-206, 1999.
8. Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hör G: Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med, 25: 1277-1283, 1998.
9. O'Byrne KJ, O'Hare N, Sweeney E, Freyne PJ, Cullen MJ: Somatostatin and somatostatin analogues in medullary thyroid carcinoma. Nucl Med Commun, 17: 810-816, 1996.
10. Wiesner W, Engel H, von Schulthess GK, Krestin GP, Bick I: FDG PET-negative liver metastases of a malignant melanoma and FDG-positive Hürthle cell tumor of the thyroid. Eur Radiol, 9: 975-978, 1999.
11. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A: The value of fluorine-18 fluorodeoxyglucose in patients with medullary thyroid cancer. Eur J Nucl Med, 27: 490-496, 2000.
12. Mazzaferri EL: Management of a solitary thyroid nodule. N Engl J Med, 328: 553-559, 1993.
13. Gharib H, Goellner JR: Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med, 118: 282-289, 1993.
14. Adler LP, Bloom AD: Positron emission tomography of thyroid masses. Thyroid, 3: 195-200, 1993.
15. Uematsu H, Sadato N, Ohtsubo T, Tsuchida T, Nakamura S, Sugimoto K, Waki A, Takahashi N, Yonekura Y, Tsuda G, Saito H, Hayashi N, Yamamoto K, Ishii Y: Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. J Nucl Med, 39: 453-459, 1998.
16. Reimer S, Adler LP, Bloom AD: Prospective evaluation of PET-FDG in FNA indeterminate thyroid nodules. J Nucl Med, 39: 123, 1998.
17. Yasuda S, Shohtsu A: Cancer screening with whole-body 18F-fluorodeoxyglucose positron-emission tomography. Lancet, 350: 1819, 1997.
18. Yasuda S, Shohtsu A, Ide M, Takagi S, Takahashi W, Suzuki Y, Horiuchi M: Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology, 207: 775-778, 1998.
19. Lawson MA, Chen K, Seabold JE: Incidental thyroid metabolomas: focal FDG thyroid gland uptake observed in patients undergoing PET imaging for metabolic assessment of pulmonary nodules, tumor staging and evaluation of cancer recurrences. Thyroid, 2003 (submitted).
20. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H: Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med, 24: 1342-1348, 1997.
21. Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY: Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med, 40: 986-992, 1999.
22. Conti PS, Durski JM, Bacqai F, Grafto ST, Singer PA: Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid, 9: 797-804, 1999.
23. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ: PET scanning with [18F] 2-fluoro-2 deoxy-D-glucose (FDG) can localize residual differentiated thyroid cancer in patients with negative [131I]-iodine whole-body scans. J Clin Endocrinol Metab, 84: 2291-2302, 1999.
24. Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schafers M, Schober O: Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langlebecks Arch Surg, 383: 160-163, 1998.
25. Jadvar H, McDougall IR, Segall GM: Evaluation of suspected recurrent papillary thyroid carcinoma with [18F] fluorodeoxyglucose positron emission tomography. Nucl Med Comm, 19: 547-554, 1998.
26. Huang TS, Chieng PU, Chang CC, Yen RF: Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: two case reports. J Endocrinol Invest, 21: 392-398, 1998.
27. Van Tol KM, Jager PI, Dullaart RPF, Links TP: Follow-up in patients with differentiated thyroid carcinoma with positive 18F 2-fluoro-2 deoxy-D-glucose positron emission tomography results, elevated thyroglobulin levels, and negative high-dose 131I post-treatment whole-body scans. J Clin Endocrinol Metab, 85: 2082-2083, 2000.
28. Alnafisi NS, Driedger AA, Cates G, Moote DJ, Raphael SJ: FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med, 41: 1010-1015, 2000.
29. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, Gomez MJ, Rodriguez-Fernandez A, Muros T, Lopez de la Torre M, Becerra A, Carreras JL: Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg, 179: 457-461, 2000.
30. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, Schober O, Lerch H, Brandt-Mainz K, Burchert W, Hiltermann G, Cremerius U, Biersack HJ: Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med, 26: 1547-1552, 1999.
31. Cook GJR, Maisey MN, Fogelman I: Normal variants, artefacts and interpretative pitfalls in PET with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med, 26: 1363-1378, 1999.
32. Barrington SF, Maisey MN: Skeletal muscle uptake of fluorine-18 FDG; effect of oral diazepam. J Nucl Med, 37: 1127-1129, 1996.
33. Sisson JC, Ackerman RJ, Meyer MA, Wahl RL: Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metabol, 77: 1090-1094, 1993.
34. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH: Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging, 29: 641-647, 2002.
35. Musholt TJ, Musholt PB, Dehdashti F, Moley JF: Evaluation of fluorodeoxyglucose-positron emission tomography scanning and its association with glucose transporter expression in medullary thyroid cancer and pheochromocytoma: a clinical and molecular study. Surgery, 122: 1049-1060, 1997.
36. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F: Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med, 28: 1671-1676, 2001.
37. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G: Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med, 25: 79-83, 1998.
38. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E: 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med, 28: 64-71, 2001.